The nonrandomized phase I/II RELATIVITY-048 trial—results of which were presented by Ascierto et al at the 2024 ASCO Annual Meeting (Abstract 9504)—investigated the efficacy of the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab in the first-line treatment of advanced melanoma.
